Exosome-targeting bispecific antibodies
The inventions described herein are directed to bispecific antibodies that are capable of selectively targeting exosomes by specifically binding a first exosome-associated protein and Programmed Death Ligand-1 ("PD-L1") as a second exosome-associated protein. These bispecific antibodies ca...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | MORIN, Michael John ROBINSON, Matthew K |
| description | The inventions described herein are directed to bispecific antibodies that are capable of selectively targeting exosomes by specifically binding a first exosome-associated protein and Programmed Death Ligand-1 ("PD-L1") as a second exosome-associated protein. These bispecific antibodies can disrupt the suppression of anti-tumor activity by immune cells by targeting tumor-cell derived exosomes that inhibit T cell activation. Therefore, bispecific antibodies of the invention can be used in methods for treating cancers. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_AU2019359877A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>AU2019359877A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_AU2019359877A13</originalsourceid><addsrcrecordid>eNrjZFB3rcgvzs9N1S1JLEpPLcnMS1dIyiwuSE3OTMtMVkjMK8lMyk_JTC3mYWBNS8wpTuWF0twMym6uIc4euqkF-fGpxQWJyal5qSXxjqFGBoaWxqaWFubmjobGxKkCAG40KUk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Exosome-targeting bispecific antibodies</title><source>esp@cenet</source><creator>MORIN, Michael John ; ROBINSON, Matthew K</creator><creatorcontrib>MORIN, Michael John ; ROBINSON, Matthew K</creatorcontrib><description>The inventions described herein are directed to bispecific antibodies that are capable of selectively targeting exosomes by specifically binding a first exosome-associated protein and Programmed Death Ligand-1 ("PD-L1") as a second exosome-associated protein. These bispecific antibodies can disrupt the suppression of anti-tumor activity by immune cells by targeting tumor-cell derived exosomes that inhibit T cell activation. Therefore, bispecific antibodies of the invention can be used in methods for treating cancers.</description><language>eng</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2021</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210520&DB=EPODOC&CC=AU&NR=2019359877A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,777,882,25545,76296</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210520&DB=EPODOC&CC=AU&NR=2019359877A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>MORIN, Michael John</creatorcontrib><creatorcontrib>ROBINSON, Matthew K</creatorcontrib><title>Exosome-targeting bispecific antibodies</title><description>The inventions described herein are directed to bispecific antibodies that are capable of selectively targeting exosomes by specifically binding a first exosome-associated protein and Programmed Death Ligand-1 ("PD-L1") as a second exosome-associated protein. These bispecific antibodies can disrupt the suppression of anti-tumor activity by immune cells by targeting tumor-cell derived exosomes that inhibit T cell activation. Therefore, bispecific antibodies of the invention can be used in methods for treating cancers.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2021</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZFB3rcgvzs9N1S1JLEpPLcnMS1dIyiwuSE3OTMtMVkjMK8lMyk_JTC3mYWBNS8wpTuWF0twMym6uIc4euqkF-fGpxQWJyal5qSXxjqFGBoaWxqaWFubmjobGxKkCAG40KUk</recordid><startdate>20210520</startdate><enddate>20210520</enddate><creator>MORIN, Michael John</creator><creator>ROBINSON, Matthew K</creator><scope>EVB</scope></search><sort><creationdate>20210520</creationdate><title>Exosome-targeting bispecific antibodies</title><author>MORIN, Michael John ; ROBINSON, Matthew K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_AU2019359877A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2021</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>MORIN, Michael John</creatorcontrib><creatorcontrib>ROBINSON, Matthew K</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>MORIN, Michael John</au><au>ROBINSON, Matthew K</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Exosome-targeting bispecific antibodies</title><date>2021-05-20</date><risdate>2021</risdate><abstract>The inventions described herein are directed to bispecific antibodies that are capable of selectively targeting exosomes by specifically binding a first exosome-associated protein and Programmed Death Ligand-1 ("PD-L1") as a second exosome-associated protein. These bispecific antibodies can disrupt the suppression of anti-tumor activity by immune cells by targeting tumor-cell derived exosomes that inhibit T cell activation. Therefore, bispecific antibodies of the invention can be used in methods for treating cancers.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_AU2019359877A1 |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
| title | Exosome-targeting bispecific antibodies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T18%3A46%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=MORIN,%20Michael%20John&rft.date=2021-05-20&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EAU2019359877A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |